Understanding How Tau Protein Harms Brain Cells in Alzheimer's

Hyperphosphorylated tau and the molecular mechanisms of tauopathy

NIH-funded research Michigan State University · NIH-11297282

This project aims to discover how a specific protein called tau becomes toxic to brain cells in conditions like Alzheimer's disease.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionMichigan State University NIH-funded
Lab location1 site (East Lansing, United States)
Project IDNIH-11297282 on NIH RePORTER

What this research studies

Alzheimer's disease and similar conditions are linked to an abnormal tau protein that becomes hyperphosphorylated and toxic to brain cells. We want to understand exactly how this altered tau protein damages cells and what makes it so harmful. By studying hyperphosphorylated tau, we hope to pinpoint the molecular steps involved in its toxicity and transmission. This knowledge could help us identify new targets for future medications. We are also looking for specific changes in the tau protein that drive its disease-causing effects.

Who could benefit from this research

Good fit: Patients with Alzheimer's disease or other tauopathies could potentially benefit from future therapies that emerge from this basic science research.

Not a fit: Patients seeking immediate treatment options will not directly participate in or benefit from this laboratory-based research.

Why it matters

Potential benefit: If successful, this foundational work could lead to the development of new drug targets and more effective treatments for Alzheimer's disease and other related conditions.

How similar studies have performed: While the role of tau in neurodegenerative diseases is well-known, this project explores the precise molecular mechanisms of its toxicity and transmission, which is a novel and critical area of investigation.

Where this research is happening

East Lansing, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer disease dementiaAlzheimer syndromeAlzheimer's DiseaseAlzheimer's disease therapeutic
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.